November 20, 2009

ATTN: Medical Health Officers and Branch Offices  
Public Health Nursing Administrators and Assistant Administrators  
Holders of Communicable Disease Control Manuals

Re: Revisions to Communicable Disease Control Manual:  
Chapter 2 – Immunization Program, Section VII – Biological Products

Please note the following:

Page 30a, pH1N1 Influenza Vaccine (Arepanrix™):
- In the contraindications section, added “History of severe oculorespiratory syndrome (ORS) that resulted in hospitalization following receipt of influenza vaccine.” This recommendation comes from the Pandemic Vaccine Task Group Guidance Document on the Use of Pandemic Influenza A (H1N1) 2009 Inactivated Monovalent Vaccine (Revised November 13, 2009).

Page 30b, pH1N1 Influenza Vaccine (Arepanrix™):
- Re-dated to have the same date as the other H1N1 pages

Page 30c, Influenza A (H1N1) 2009 Pandemic Monovalent Vaccine (Without Adjuvant):
- Replaced the indication of “Healthy individuals 10 to 64 years of age” with the following indication: “Individuals ≥ 3 years of age who request unadjuvanted vaccine.” This change was made as there is a need to conserve unadjuvanted vaccine for pregnant women.
- Added dosing information for the unadjuvanted product: “Children aged 3 – 9 years require 2 doses of 0.5 ml IM (21 days apart); others are to receive one dose of 0.5 ml IM.” These recommendations are consistent with the recommendations in the Pandemic Vaccine Task Group Guidance Document on the Use of Pandemic Influenza A (H1N1) 2009 Inactivated Monovalent Vaccine (Revised November 13, 2009).
- Added contraindication pertaining to ORS, as was done for page 30a.

Administrative Circular 2009:26
Page 30d, pH1N1 Influenza Vaccine (Unadjuvanted) Clinical Formulation:

- Indication (1) now states “Pregnant women at any stage of pregnancy.” As initial supplies of unadjuvanted vaccine were limited, the previous indication had been “Pregnant women in the first half of pregnancy.”
- Added the following indication: “Individuals ≥ 3 years of age who request unadjuvanted vaccine,” and dosing information as specified above.
- Added contraindication pertaining to ORS, as was done for page 30a.

Please remove and destroy the following pages from the Communicable Disease Control Manual, Chapter 2 – Immunization Program: Section VII – Biological Products

Pages 30a to 30c  Dated November 13, 2009
Page 30d  Dated November 5, 2009

Please insert the following pages in the Communicable Disease Control Manual, Chapter 2 – Immunization Program: Section VII – Biological Products

Pages 30a to 30d  Dated November 20, 2009

If you have any questions or concerns, please contact Karen Pielak, Nurse Epidemiologist, or Cheryl McIntyre, Associate Nurse Epidemiologist, at telephone (604) 707-2510, fax (604) 707-2516 or by email at karen.pielak@bccdc.ca or cheryl.mcintyre@bccdc.ca

Sincerely,

[Signature]

Dr. Monika Naus,
Medical Director, Immunization Program and
Associate Medical Director, Epidemiology Services
BC Centre for Disease Control
pc: Ministry of Healthy Living and Sport:

Dr. Perry Kendall              Dr. Eric Young
Provincial Health Officer          Deputy Provincial Health Officer

Dr. Bob Fisk                  Craig Thompson
Medical Consultant            Director, CD Prevention – Immunization
Non-Communicable Disease

Warren O’Briain
Executive Director
Communicable Disease and Addiction Prevention